Review



src y416 (pab25310  (Abnova)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    Abnova src y416 (pab25310
    Compared to empty vector, WT-ASPH significantly enhanced metastatic capability of MDA-MB-231 cells, which was efficiently reversed by the SMI in experimental pulmonary metastatic (tail vein injection) murine model. (A) Experimental design and (B) Therapeutic protocol for tail vein injection model (n = 5/group). (C) Using fluorescent imaging system to detect potential pulmonary metastasis in mice from different groups of tail vein injection model. (D) The number of macro-metastases in the lungs derived from mice in tail vein injection model. *P < 0.05; **P < 0.01. (E) Gross appearance of the lungs derived from representative mice in tail vein injection model. Metastatic lesions were highlighted with yellow arrows. (F) Gross appearance and histopathologic characteristics of (Upper) hepatic and (Bottom) pulmonary metastatic lesions of a representative mouse in ASPH+DMSO group of tail vein injection model. Noted the metastatic lesions also maintain high expression of ASPH. This animal was euthanized at 7th weeks. (G) Gross appearance of bone (spine) metastasis derived from a representative mouse in tail vein injection model. The mouse was tail vein injected with ASPH overexpressing MDA-MB-231 cells and treated with DMSO. (H) Histologic characteristics of bone and lung lesions in this specific mouse in (P). (I, J) Expression profiling of key components in <t>SRC</t> signaling pathway (p-SRC <t>Y416,</t> SRC regulator ADAM12 and downstream MMPs) was substantially downregulated by SMI.
    Src Y416 (Pab25310, supplied by Abnova, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/src y416 (pab25310/product/Abnova
    Average 90 stars, based on 1 article reviews
    src y416 (pab25310 - by Bioz Stars, 2026-03
    90/100 stars

    Images

    1) Product Images from "Multi-organ metastasis as destination for breast cancer cells guided by biomechanical architecture"

    Article Title: Multi-organ metastasis as destination for breast cancer cells guided by biomechanical architecture

    Journal: American Journal of Cancer Research

    doi:

    Compared to empty vector, WT-ASPH significantly enhanced metastatic capability of MDA-MB-231 cells, which was efficiently reversed by the SMI in experimental pulmonary metastatic (tail vein injection) murine model. (A) Experimental design and (B) Therapeutic protocol for tail vein injection model (n = 5/group). (C) Using fluorescent imaging system to detect potential pulmonary metastasis in mice from different groups of tail vein injection model. (D) The number of macro-metastases in the lungs derived from mice in tail vein injection model. *P < 0.05; **P < 0.01. (E) Gross appearance of the lungs derived from representative mice in tail vein injection model. Metastatic lesions were highlighted with yellow arrows. (F) Gross appearance and histopathologic characteristics of (Upper) hepatic and (Bottom) pulmonary metastatic lesions of a representative mouse in ASPH+DMSO group of tail vein injection model. Noted the metastatic lesions also maintain high expression of ASPH. This animal was euthanized at 7th weeks. (G) Gross appearance of bone (spine) metastasis derived from a representative mouse in tail vein injection model. The mouse was tail vein injected with ASPH overexpressing MDA-MB-231 cells and treated with DMSO. (H) Histologic characteristics of bone and lung lesions in this specific mouse in (P). (I, J) Expression profiling of key components in SRC signaling pathway (p-SRC Y416, SRC regulator ADAM12 and downstream MMPs) was substantially downregulated by SMI.
    Figure Legend Snippet: Compared to empty vector, WT-ASPH significantly enhanced metastatic capability of MDA-MB-231 cells, which was efficiently reversed by the SMI in experimental pulmonary metastatic (tail vein injection) murine model. (A) Experimental design and (B) Therapeutic protocol for tail vein injection model (n = 5/group). (C) Using fluorescent imaging system to detect potential pulmonary metastasis in mice from different groups of tail vein injection model. (D) The number of macro-metastases in the lungs derived from mice in tail vein injection model. *P < 0.05; **P < 0.01. (E) Gross appearance of the lungs derived from representative mice in tail vein injection model. Metastatic lesions were highlighted with yellow arrows. (F) Gross appearance and histopathologic characteristics of (Upper) hepatic and (Bottom) pulmonary metastatic lesions of a representative mouse in ASPH+DMSO group of tail vein injection model. Noted the metastatic lesions also maintain high expression of ASPH. This animal was euthanized at 7th weeks. (G) Gross appearance of bone (spine) metastasis derived from a representative mouse in tail vein injection model. The mouse was tail vein injected with ASPH overexpressing MDA-MB-231 cells and treated with DMSO. (H) Histologic characteristics of bone and lung lesions in this specific mouse in (P). (I, J) Expression profiling of key components in SRC signaling pathway (p-SRC Y416, SRC regulator ADAM12 and downstream MMPs) was substantially downregulated by SMI.

    Techniques Used: Plasmid Preparation, Injection, Imaging, Derivative Assay, Expressing



    Similar Products

    src y416 (pab25310  (Abnova)
    90
    Abnova src y416 (pab25310
    Compared to empty vector, WT-ASPH significantly enhanced metastatic capability of MDA-MB-231 cells, which was efficiently reversed by the SMI in experimental pulmonary metastatic (tail vein injection) murine model. (A) Experimental design and (B) Therapeutic protocol for tail vein injection model (n = 5/group). (C) Using fluorescent imaging system to detect potential pulmonary metastasis in mice from different groups of tail vein injection model. (D) The number of macro-metastases in the lungs derived from mice in tail vein injection model. *P < 0.05; **P < 0.01. (E) Gross appearance of the lungs derived from representative mice in tail vein injection model. Metastatic lesions were highlighted with yellow arrows. (F) Gross appearance and histopathologic characteristics of (Upper) hepatic and (Bottom) pulmonary metastatic lesions of a representative mouse in ASPH+DMSO group of tail vein injection model. Noted the metastatic lesions also maintain high expression of ASPH. This animal was euthanized at 7th weeks. (G) Gross appearance of bone (spine) metastasis derived from a representative mouse in tail vein injection model. The mouse was tail vein injected with ASPH overexpressing MDA-MB-231 cells and treated with DMSO. (H) Histologic characteristics of bone and lung lesions in this specific mouse in (P). (I, J) Expression profiling of key components in <t>SRC</t> signaling pathway (p-SRC <t>Y416,</t> SRC regulator ADAM12 and downstream MMPs) was substantially downregulated by SMI.
    Src Y416 (Pab25310, supplied by Abnova, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/src y416 (pab25310/product/Abnova
    Average 90 stars, based on 1 article reviews
    src y416 (pab25310 - by Bioz Stars, 2026-03
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    Compared to empty vector, WT-ASPH significantly enhanced metastatic capability of MDA-MB-231 cells, which was efficiently reversed by the SMI in experimental pulmonary metastatic (tail vein injection) murine model. (A) Experimental design and (B) Therapeutic protocol for tail vein injection model (n = 5/group). (C) Using fluorescent imaging system to detect potential pulmonary metastasis in mice from different groups of tail vein injection model. (D) The number of macro-metastases in the lungs derived from mice in tail vein injection model. *P < 0.05; **P < 0.01. (E) Gross appearance of the lungs derived from representative mice in tail vein injection model. Metastatic lesions were highlighted with yellow arrows. (F) Gross appearance and histopathologic characteristics of (Upper) hepatic and (Bottom) pulmonary metastatic lesions of a representative mouse in ASPH+DMSO group of tail vein injection model. Noted the metastatic lesions also maintain high expression of ASPH. This animal was euthanized at 7th weeks. (G) Gross appearance of bone (spine) metastasis derived from a representative mouse in tail vein injection model. The mouse was tail vein injected with ASPH overexpressing MDA-MB-231 cells and treated with DMSO. (H) Histologic characteristics of bone and lung lesions in this specific mouse in (P). (I, J) Expression profiling of key components in SRC signaling pathway (p-SRC Y416, SRC regulator ADAM12 and downstream MMPs) was substantially downregulated by SMI.

    Journal: American Journal of Cancer Research

    Article Title: Multi-organ metastasis as destination for breast cancer cells guided by biomechanical architecture

    doi:

    Figure Lengend Snippet: Compared to empty vector, WT-ASPH significantly enhanced metastatic capability of MDA-MB-231 cells, which was efficiently reversed by the SMI in experimental pulmonary metastatic (tail vein injection) murine model. (A) Experimental design and (B) Therapeutic protocol for tail vein injection model (n = 5/group). (C) Using fluorescent imaging system to detect potential pulmonary metastasis in mice from different groups of tail vein injection model. (D) The number of macro-metastases in the lungs derived from mice in tail vein injection model. *P < 0.05; **P < 0.01. (E) Gross appearance of the lungs derived from representative mice in tail vein injection model. Metastatic lesions were highlighted with yellow arrows. (F) Gross appearance and histopathologic characteristics of (Upper) hepatic and (Bottom) pulmonary metastatic lesions of a representative mouse in ASPH+DMSO group of tail vein injection model. Noted the metastatic lesions also maintain high expression of ASPH. This animal was euthanized at 7th weeks. (G) Gross appearance of bone (spine) metastasis derived from a representative mouse in tail vein injection model. The mouse was tail vein injected with ASPH overexpressing MDA-MB-231 cells and treated with DMSO. (H) Histologic characteristics of bone and lung lesions in this specific mouse in (P). (I, J) Expression profiling of key components in SRC signaling pathway (p-SRC Y416, SRC regulator ADAM12 and downstream MMPs) was substantially downregulated by SMI.

    Article Snippet: As previously described [ 22 - 24 ], IHC was performed on 4-μm thick FFPE slides with antibodies to ASPH (FB50, homemade); MMP1 (ab38929), MMP14 (ab3644) from Abcam (Cambridge, MA); SRC Y416 ( {"type":"entrez-protein","attrs":{"text":"PAB25310","term_id":"1236638637","term_text":"PAB25310"}} PAB25310 ) from Abnova (Taipei, Taiwan) and ADAM12 (14139-1-AP) from Proteintech (Rosemont, IL).

    Techniques: Plasmid Preparation, Injection, Imaging, Derivative Assay, Expressing